| Name | Title | Contact Details |
|---|---|---|
Alex Kelly |
Associate General Counsel | Profile |
Patrick Dandino |
General Counsel | Profile |
Memorial Home Services is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Harbor House Alcohol Drug Center is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
NYC Health + Hospitals is the nation`s largest public health care delivery system. We are an integrated network of hospitals, trauma centers, neighborhood health centers, nursing homes, and post-acute care centers. We are a home care agency and a health plan, MetroPlus. The health system provides essential services to more than 1.4 million New Yorkers every year in more than 70 patient care locations and in their homes. Our talented workforce of more than 40,000 represents the diversity of our city and the communities we serve. The excellence of our staff, and our continued mission to care for all without exception, make us unique and rightly positioned to provide equitable, high-quality, culturally responsive, and affordable health care in every New York City community. Our promise to New Yorkers: Empower every New Yorker – without exception – to live the healthiest life possible by providing equitable, high quality, culturally responsive, and affordable health care in every community.
Monarch Medical Technologies is a digital health company committed to helping hospitals and health systems deliver optimal glycemic management for critical care and non-critical care patients alike. Insulin dosing has always been a daunting and time-intensive task, but now that burnout and staffing constraints have reached record highs, never have the associated risks and challenges been more acute. Add the impacts of new CMS measures for hyperglycemia and hypoglycemia, and you have the perfect storm. Our FDA-cleared EndoTool® Glucose Management System is designed specifically to displace traditional manual methods of insulin dosing with an intuitive and easy-to-use software application that integrates seamlessly with your EMR. This pioneering clinical decision support platform offers both intravenous and subcutaneous modalities, and has been shown to safely and reliably achieve and maintain target glucose goals. Specialized features help clinicians address the complexities surrounding diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic nonketotic syndrome (HHS), gestational diabetes, kidney function, residual insulin, and presence of steroids.
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.